All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
TOKYO – In a world's first, Japan-based Sanbio Inc. will conduct a phase II global trial into a treatment for chronic traumatic brain injury with allogeneic stem cells.
